Cellectar Biosciences (CLRB) News and press releases

Cellectar Biosciences (NASDAQ:CLRB) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Cellectar Biosciences reported in-line EPS of $-0.1 versus an estimate of $-0.1.

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.10) per share. This is a 23.08 percent increase over losses of $(0.13) per share from the same period last year.

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced

Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.

Gainers

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a loss of 1

Cellectar Biosciences (NASDAQ:CLRB) reported its Q4 earnings results on Monday, March 21, 2022 at 08:30 AM. Here's what investors need to know about the announcement.

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted

New York, United States, Wed, 30 Mar 2022 06:50:07 / Comserve Inc. / -- The market for neuroblastoma drugs is anticipated to record a notable CAGR of around 4% over the forecast period 2020-2028. Research Nester